- March 12, 2021
- Category: Drugs and Therapeutics, Healthcare and LifeSciences
Global Erythropoietin Drugs Market Size study, By Drug Class (Biologics, Biosimilars), By Product (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others), By Application (Cancer, Hematology, Neurology and Renal Diseases) and Regional Forecasts 2021-2027
Chapter 1.Executive Summary 1.1. Market Snapshot 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2027 (USD Billion) 1.2.1. Erythropoietin Drugs Market, by Drug Class, 2019-2027 (USD Billion) 1.2.2. Erythropoietin Drugs Market, by Product, 2019-2027 (USD Billion) 1.2.3. Erythropoietin Drugs Market, by Application, 2019-2027 (USD Billion) 1.2.4. Erythropoietin Drugs Market, by, 2019-2027 (USD Billion) 1.2.5. Erythropoietin Drugs Market, by, 2019-2027 (USD Billion) 1.3. Key Trends 1.4. Estimation Methodology 1.5. Research Assumption Chapter 2. Global Erythropoietin Drugs Market Definition and Scope 2.1. Objective of the Study 2.2. Market Definition & Scope 2.2.1. Scope of the Study 2.2.2. Industry Evolution 2.3. Years Considered for the Study 2.4. Currency Conversion Rates Chapter 3. Global Erythropoietin Drugs Market Dynamics 3.1. Erythropoietin Drugs Market Impact Analysis (2019-2027) 3.1.1. Market Drivers 126.96.36.199. Increasing demand from patients of HIV and kidney Diseases 188.8.131.52. Rising incidence of diabetes and heart diseases 3.1.2. Market Challenges 184.108.40.206. High cost of production of drugs 3.1.3. Market Opportunities 220.127.116.11. Patent expiration of major drug manufacturers Chapter 4. Global Erythropoietin Drugs Market Industry Analysis 4.1. Porter’s 5 Force Model 4.1.1. Bargaining Power of Suppliers 4.1.2. Bargaining Power of Buyers 4.1.3. Threat of New Entrants 4.1.4. Threat of Substitutes 4.1.5. Competitive Rivalry 4.1.6. Futuristic Approach to Porter’s 5 Force Model (2018-2027) 4.2. PEST Analysis 4.2.1. Political 4.2.2. Economical 4.2.3. Social 4.2.4. Technological 4.3. Investment Adoption Model 4.4. Analyst Recommendation & Conclusion Chapter 5. Global Erythropoietin Drugs Market, by Drug Class 5.1. Market Snapshot 5.2. Global Erythropoietin Drugs Market by Drug Class, Performance - Potential Analysis 5.3. Global Erythropoietin Drugs Market Estimates & Forecasts by Drug Class 2018-2027 (USD Billion) 5.4. Erythropoietin Drugs Market, Sub Segment Analysis 5.4.1. Biologics 5.4.2. Biosimilars Chapter 6. Global Erythropoietin Drugs Market, by Product 6.1. Market Snapshot 6.2. Global Erythropoietin Drugs Market by Product, Performance - Potential Analysis 6.3. Global Erythropoietin Drugs Market Estimates & Forecasts by Product 2018-2027 (USD Billion) 6.4. Erythropoietin Drugs Market, Sub Segment Analysis 6.4.1. Epoetin-alfa 6.4.2. Epoetin-beta 6.4.3. Darbepoetin-alfa 6.4.4. Others Chapter 7. Global Erythropoietin Drugs Market, by Application 7.1. Market Snapshot 7.2. Global Erythropoietin Drugs Market by Application, Performance - Potential Analysis 7.3. Global Erythropoietin Drugs Market Estimates & Forecasts by Application 2018-2027 (USD Billion) 7.4. Erythropoietin Drugs Market, Sub Segment Analysis 7.4.1. Cancer 7.4.2. Haematology 7.4.3. Renal Diseases 7.4.4. Neurology Chapter 8. Global Erythropoietin Drugs Market, Regional Analysis 8.1. Erythropoietin Drugs Market, Regional Market Snapshot 8.2. North America Erythropoietin Drugs Market 8.2.1. U.S. Erythropoietin Drugs Market 18.104.22.168. Drug Class breakdown estimates & forecasts, 2018-2027 22.214.171.124. Product breakdown estimates & forecasts, 2018-2027 126.96.36.199. Application breakdown estimates & forecasts, 2018-2027 8.2.2. Canada Erythropoietin Drugs Market 8.3. Europe Erythropoietin Drugs Market Snapshot 8.3.1. U.K. Erythropoietin Drugs Market 8.3.2. Germany Erythropoietin Drugs Market 8.3.3. France Erythropoietin Drugs Market 8.3.4. Spain Erythropoietin Drugs Market 8.3.5. Italy Erythropoietin Drugs Market 8.3.6. Rest of Europe Erythropoietin Drugs Market 8.4. Asia-Pacific Erythropoietin Drugs Market Snapshot 8.4.1. China Erythropoietin Drugs Market 8.4.2. India Erythropoietin Drugs Market 8.4.3. Japan Erythropoietin Drugs Market 8.4.4. Australia Erythropoietin Drugs Market 8.4.5. South Korea Erythropoietin Drugs Market 8.4.6. Rest of Asia Pacific Erythropoietin Drugs Market 8.5. Latin America Erythropoietin Drugs Market Snapshot 8.5.1. Brazil Erythropoietin Drugs Market 8.5.2. Mexico Erythropoietin Drugs Market 8.6. Rest of The World Erythropoietin Drugs Market Chapter 9. Competitive Intelligence 9.1. Top Market Strategies 9.2. Company Profiles 9.2.1. Johnson & Johnson 188.8.131.52. Key Information 184.108.40.206. Overview 220.127.116.11. Financial (Subject to Data Availability) 18.104.22.168. Product Summary 22.214.171.124. Recent Developments 9.2.2. Celltrion, Inc. 9.2.3. Teva Pharmaceutical Industries Ltd 9.2.4. Amgen, Inc. 9.2.5. Hoffman-La Roche Ltd. 9.2.6. LG Life Sciences Ltd. 9.2.7. Biocon Limited 9.2.8. Intas Pharmaceuticals Ltd. 9.2.9. Sun Pharmaceutical Industries Ltd. 9.2.10. Dr. Reddy’s Laboratories Ltd. Chapter 10. Research Process 10.1. Research Process 10.1.1. Data Mining 10.1.2. Analysis 10.1.3. Market Estimation 10.1.4. Validation 10.1.5. Publishing 10.2. Research Attributes 10.3. Research Assumption
Global Erythropoietin Drugs Market is valued approximately USD 11.05 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 11.30% over the forecast period 2021-2027. Erythropoietin is a hormone produced by the kidney that encourages the formation of red blood cells by the bone marrow. The subsequent rise in red cells increases the oxygen-carrying capacity of the blood. Erythropoietin drugs are used as a medication to treat anemia (low red blood cell count) in patients with long-term serious kidney disease (chronic kidney failure), people receiving zidovudine to treat HIV, and people receiving chemotherapy for some types of cancer. The rise in the cases of chronic kidney diseases as well as in the patients of HIV and anemia are increasing the demand for erythropoietin drugs.
According to National Kidney Foundation in 2018, kidney disease affects an estimated 37 million people in the U.S.A. In 2018, 785,883 Americans had kidney failure, and needed dialysis or a kidney transplant to survive. Also, 12 people die every day while waiting for a kidney transplant. Centre for Disease Control reports that more than 1 in 7, that is 15% of US adults or 37 million people, are estimated to have Chronic Kidney Disease (CKD). Diabetes and high blood pressure are the usual causes of CKD in adults. Other risk factors include heart disease, obesity, a family history of disease and older age. The rising diabetic and heart patients too are causing the increased demand for erythropoietin drugs. The high cost of manufacturing erythropoietin drugs, particularly in developing countries, may act as a restraint for its growth. However, as the patents of major companies are expiring in the near future, the market for generic biologics and biosimilars is ripe to capture. This acts as an opportunity for Erythropoietin Drugs Market in subsequent decade.
Key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World are analysed to provide a holistic picture of Erythropoietin Drugs Market. Due to higher number of patients of chronic kidney diseases as well as higher per capita income and hence more expenditure on health, North America is a significant region across the world in terms of market share. Whereas, Asia-Pacific is expected to exhibit highest growth rate for the forecast period 2021-2027 owing to the increasing cases of anemia and HIV in developing countries. Rising disposable income and government as well as private investment in healthcare sector will also boost growth in this region.
Major market player included in this report are:
Johnson & Johnson
Teva Pharmaceutical Industries Ltd
Hoffman-La Roche Ltd.
LG Life Sciences Ltd.
Intas Pharmaceuticals Ltd.
Sun Pharmaceutical Industries Ltd.
Dr. Reddy’s Laboratories Ltd.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Class:
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2018, 2019
Base year – 2020
Forecast period – 2021 to 2027
Target Audience of the Global Erythropoietin Drugs Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Value-Added Resellers (VARs)
Third-party knowledge providers